Gene Therapy Composition for Treating Eye Diseases
Summary
The European Patent Office published patent application EP4185333A1 by FTM GEN Corp for a gene therapy composition and method treating eye diseases. The application, filed by inventors SHI Zhongdong and ZHAO Wei, covers therapeutic applications using gene delivery technology (A61K 48/00). The designated states include all EU member states plus other European Economic Area countries.
What changed
The EPO published European patent application EP4185333A1 for a composition and method for treating eye diseases using gene therapy. The application (IPC classification A61K 48/00, C12N 15/63) names FTM GEN Corp as the applicant and SHI Zhongdong and ZHAO Wei as inventors. The filing is designated for all 35 European states including Germany, France, the UK, Italy, Spain, and other EU/EEA members.
Patent publications do not impose compliance obligations on pharmaceutical companies or healthcare providers. Entities developing gene therapy treatments for ophthalmic conditions should review the published claims to assess potential freedom-to-operate implications for their own product development programs.
Source document (simplified)
COMPOSITION AND METHOD FOR TREATING EYE DISEASES
Publication EP4185333A1 Kind: A1 Mar 25, 2026
Applicants
FTGEN Corp
Inventors
SHI, Zhongdong, ZHAO, Wei
IPC Classifications
A61K 48/00 20060101AFI20240730BHEP C12N 15/63 20060101ALI20240730BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.